Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Saturday, April 30, 2016

ClinicSpeak: natalizumab or alemtuzumab?

                                                                  

Click here to receive MS news via e-mail        
 



Friday, 15 August 2014

ClinicSpeak: natalizumab or alemtuzumab?

Wow, MS DMT counselling just got very complicated. Natalizumab vs. Alemtuzumab#ClinicSpeak #MSBlog #MSResearch

"In clinic on Tuesday I saw two  patients with rapidly-evolving severe MS who were eligible for natalizumab under the current NHS England's guidelines. One patient was a young man naive to first-line treatment with a poor prognostic profile (high lesion load on MRI, including posterior fossa lesions, and early disability in motor and cerebellar systems). The second patient is a young woman failing fingolinod (two disabling relapses in the last 6 months) having previously failed interferon-beta. Up until now the discussion for both of these patients would have been simple and I would have offered them natalizumab. I have a well-oiled summary of the risks and benefits of natalizumab and how we manage and de-risk the PML problem if they happen to be JCV-seropositive. But things have changed, we now have alemtuzumab as a therapeutic option for these patients. When I started discussing alemtuzumab next to natalizumab with these two patients things got very complicated."

"How do you compare a maintenance and an induction strategy with each other? When I mentioned the rates of long-term remission on alemtuzumab, and the potential an induction therapy offers regarding a cure, things got messy. I now realise that I can't mention the C-word without defining it. When I tried to define the C-word and discussed the potential of a cure, both patients were lost. Despite this it was clear that a potential cure is the alemtuzumab trump card. The promise of long-term remission, and a potential cure, is what outweighs the risks of being treated with alemtuzumab."




~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News
Provides educational information, resources and services for those affected by MS
We Believe YOU (the MS Patients and Caregivers) should Be Empowered with Multiple Sclerosis information
.===================================





No comments: